MTOR and hypertensive disorder: Calcineurin inhibitors promote cardiac hypertrophy, hypertension, dyslipidemia, and vascular remodeling, while mTOR inhibitors have an anti-proliferative effect with attenuation of cardiac hypertrophy and vascular remodeling despite promoting dyslipidemia.